Majid Vakilynejad

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

Charles Burant, Prabhakar Viswanathan, John Marcinak et al. · The Lancet · 2012 · 243 citations

Metabolic Syndrome, Diabetes Management, Tak-875 Versus Placebo +5

A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes

Eckhard Leifke, Himanshu Naik, Jingtao Wu et al. · Clinical Pharmacology & Therapeutics · 2012 · 87 citations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK‐875: Results From a Double‐Blind, Placebo‐Controlled Single Oral Dose Rising Study in Healthy Volunteers

Himanshu Naik, Majid Vakilynejad, Jingtao Wu et al. · The Journal of Clinical Pharmacology · 2011 · 84 citations

Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques

Violeta Rodriguez‐Romero, Richard F. Bergstrom, Brian S. Decker et al. · Clinical and Translational Science · 2019 · 63 citations · Full text

Machine Learning, Disease Classification, Metabolic Syndrome +18

Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Edgar Schuck, Tonika Bohnert, Arijit Chakravarty et al. · The AAPS Journal · 2015 · 51 citations · Full text

Translational Medicine, Pharmacokinetic Modeling, Pharmacology +9